NOAC 'Reasonably' Cost-Effective in Afib (CME/CE)

(MedPage Today) -- Apixaban analysis shows about $54k per QALY vs warfarin
via NOAC 'Reasonably' Cost-Effective in Afib (CME/CE)
by